23:02 , Apr 10, 2019 |  BC Extra  |  Company News

Gilead cuts cardiopulmonary sales reps

Gilead said it will lay off about 150 cardiopulmonary sales representatives due to the anticipated market entry of generic versions of Letairis ambrisentan and Ranexa ranolazine. The decision was put into motion almost two years...
21:19 , Apr 10, 2019 |  BC Extra  |  Financial News

Rare genetic disease company Homology raises $125M follow-on

Homology raised $125 million in a follow-on priced late Tuesday to advance its pipeline of gene therapies. Homology Medicines Inc. (NASDAQ:FIXX) sold 5.5 million shares at $22.50. The price represents a 24% discount to the...
13:42 , Apr 8, 2019 |  BC Extra  |  Clinical News

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:25 , Mar 29, 2019 |  BC Week In Review  |  Company News

Sandoz launches first generic Remodulin in the U.S.

Sandoz launched in the U.S. the first generic version of pulmonary arterial hypertension (PAH) drug Remodulin treprostinil from United Therapeutics. The Novartis AG (NYSE:NVS; SIX:NOVN) unit said its generic has 180 days of marketing exclusivity....
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension. The...
22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
19:51 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing...
22:57 , Dec 18, 2018 |  BC Extra  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal"...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...